Today marks a historic milestone for the type 1 diabetes (T1D) community: the @US_FDA has approved Tzield for use in individuals ages 8–17 with stage 3 T1D. This is the first disease-modifying therapy ever approved for stage 3 T1D! Tzield preserves beta cell function in newly diagnosed individuals, which has been shown to result in fewer hypoglycemic events, lower insulin use, reduced burden of care, and improved A1c. We'll keep working to ensure people with stage 3 T1D everywhere, not just in the U.S., have access to therapies that help them live healthier lives. Breakthrough T1D and the T1D Fund have supported the development of this therapy for over 30 years, and we're grateful to the FDA for recognizing the urgent unmet need in T1D and expediting Tzield's approval through the accelerated approval pathway. We also thank @sanofi for their continued research and the T1D community for advocating for therapies that change the course of this disease. Read more here: breakthrought1d.org/news-and…

Whether you're walking, riding, running, or fundraising your way, the Breakthrough T1D Fundraising mobile app has everything you need! Through the app, you can check your fundraising progress, update or personalize your fundraising page, send fundraising emails and texts, post updates on social media, deposit check donations, and more! Download the Breakthrough T1D Fundraising App today from your favorite app store!

Mid-Year Mission Update x.com/i/broadcasts/1dKrPPYEn…

Pediatric endocrinologist and Senior Director of Medical Affairs at Breakthrough T1D, Brynn Marks, shares updates around a session that focused on pediatric perspectives in cell therapies and more! Be sure to stay tuned for more coverage, and join us on June 10 at 6pm ET for a mid-year mission update! You can watch across our social media channels—you won’t want to miss it!

Exciting day 3 at ADA 2026! Data from a Breakthrough T1D-funded clinical trial showed that 12 individuals are off external insulin. Watch and visit the link below to learn more about Dr. Witkowski's presentation on Eledon's tegoprubart with islet cell transplants, plus other exciting updates. breakthrought1d.org/news-and…

Lynn Starr, Breakthrough T1D’s Chief Global Advocacy Officer, speaks about how critical advocacy work is to helping move type 1 diabetes (T1D) research progress forward, and the pivotal role that data plays in our advocacy efforts. Be sure to join us on Wednesday, June 10 at 6 pm ET across our social channels for a mid-year mission update where you’ll be able to hear about all the incredible progress being made!

Breakthrough T1D CEO Dr. Aaron Kowalski shares some of the exciting type 1 diabetes (T1D) research he's looking forward to hearing about at #ADA2026! Be sure to stay tuned for more coverage, and join us on June 10 at 6pm ET for a mid-year mission update! You can tune in across our social media channels--you won't want to miss it!

Today kicks off the American Diabetes Association’s (ADA) 86th Scientific Sessions! Breakthrough T1D will be there to join the discussion about the latest-and-greatest advancements in type 1 diabetes (T1D) research, prevention, and care from the best and brightest in the field—including many researchers who are currently funded by Breakthrough T1D or have been in the past. Learn more about what we’re looking forward to at the link below, and stay tuned for updates over the next few days! breakthrought1d.org/news-and…

In an exciting update for the type 1 diabetes (T1D) community, Afrezza—a rapid-acting, inhaled mealtime insulin—was approved by the FDA for use in children and adolescents ages 6 with T1D. This makes Afrezza the first and only inhaled mealtime insulin approved for use in the pediatric T1D population. Learn more at the link below! bit.ly/4o2c4QN

Exciting news! Abbott’s Libre Duo received the CE mark in Europe! It is the first sensor to track both glucose and ketones continuously. Late last year, Breakthrough T1D, led by Chief Medical Officer Thomas Danne, convened a panel of experts to devise consensus recommendations for how continuous ketone monitoring (CKM) may improve outcomes for individuals at risk for developing diabetic ketoacidosis (DKA). This device is currently under review at the FDA in the US, and we look forward to a future in which DKA is more easily prevented and the T1D community can fully experience the benefits of CKM.

We applaud @RepKimSchrier and @RepJohnJoyce and @SenatorShaheen and @SenatorCollins for introducing the Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes (T1D) Act of 2026. The bipartisan legislation aims to increase awareness and improve early detection of T1D.  Screening and early detection of T1D can save lives, help people make important decisions about their health, and potentially change the course of this disease.  Too often, children and adults are diagnosed only after becoming critically ill. Screening for T1D can be done through a simple blood test, and ongoing monitoring can help families avoid medical emergencies and take action sooner. Take action here: breakthrought1d.org/site/Adv…

Thank you @RepDianaDeGette and @RepGusBilirakis for your leadership!

Another step forward! Our champions and Congressional Diabetes Caucus Co-Chairs @RepDianaDeGette and @RepGusBilirakis just sent a letter to the FDA noting our HHS proposal and urging a new look at the regulatory pathway for deceased donor islets. These islets can help people with type 1 diabetes today. The pathway needs to catch up, and we'll keep pushing until it does. Thank you to our champions in the House!